A Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor
Other Urinary | Urinary Bladder
What is the purpose of this trial?
This study is designed to evaluate response and survival of treatment with the combination of pembrolizumab and ramucirumab in patients with progressive metastatic TCC after immune checkpoint inhibitor treatment.
- Trial withYale University
- Start Date09/17/2020
- End Date12/14/2022
- Last Updated09/21/2020
- Study HIC#2000022801